---
title: "Cumberland Pharmaceuticals 1Q 2026: Revenue $9.13M, EPS ($0.22) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285777228.md"
description: "Cumberland Pharmaceuticals reported Q1 2026 revenue of $9.13M, down 22% from $11.71M in the prior year, with a net loss of $3.29M and diluted EPS of ($0.22). The decline was attributed to the loss of a $3.0M milestone and reduced Kristalose shipments. However, Sancuso and Vibativ saw volume growth, and Talicia contributed $1.9M. The company plans to sell its U.S. branded portfolio to Apotex for $100M while focusing on its pipeline and clinical development efforts."
datetime: "2026-05-08T21:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285777228.md)
  - [en](https://longbridge.com/en/news/285777228.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285777228.md)
---

# Cumberland Pharmaceuticals 1Q 2026: Revenue $9.13M, EPS ($0.22) — 10-Q Summary

Cumberland Pharmaceuticals reported first-quarter 2026 results showing revenue of $9.13M and a net loss attributable to common shareholders of $3.29M, or diluted EPS of ($0.22), compared with revenue of $11.71M and net income of $1.26M, or EPS $0.08, in the year-ago quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$9.13M

$11.71M

(22%)

Net income²

($3.29M)

$1.26M

(361.7%)

Diluted EPS³

($0.22)

$0.08

(375%)

_¹ Reported as “Net revenues”. ² Reported as “Net income (loss) attributable to common shareholders”. ³ Reported as “Income (loss) per share attributable to common shareholders”._

**Business Highlights**

-   Total net revenues fell to $9.1M from $11.7M, driven primarily by the loss of a $3.0M 2025 milestone and lower Kristalose shipments.
-   Sancuso and Vibativ showed volume growth; Talicia launched U.S. promotion activity and contributed $1.9M in Q1 2026.
-   Ifetroban advanced in development, receiving FDA Fast Track designation for Duchenne muscular dystrophy and continuing Phase II trials in systemic sclerosis and idiopathic pulmonary fibrosis; the company plans to retain development programs post-transaction.
-   Cumberland agreed to sell its U.S. branded portfolio to Apotex for $100M and will provide transition services while refocusing on its pipeline and clinical development efforts.

Original SEC Filing: CUMBERLAND PHARMACEUTICALS INC \[ CPIX \] - 10-Q - May. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CPIX.US](https://longbridge.com/en/quote/CPIX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)